011000.KS Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (2 geg. 2024 @ 09:30):

Stats
Šios dienos apimtis	153 015
Vidutinė apimtis	652 340
Rinkos kapitalizacija	193.59B
EPS	KRW0 ( 2023-09-30 )
Last Dividend	KRW0 ( N/A )
Next Dividend	KRW0 ( N/A )
P/E	-3.57
ATR14	KRW4.47 (0.18%)

Tūris Koreliacija

Ilgas: 0.09 (neutral)

Trumpas: 0.66 (moderate)

Signal:(49.789) Neutral

GeneOne Life Science, Koreliacija

10 Labiausiai teigiamai susiję koreliacijos

10 Labiausiai neigiamai susiję koreliacijos

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

GeneOne Life Science, Koreliacija - Valiuta/Žaliavos

0.34
( neutral )

0.31
( neutral )

0.29
( neutral )

0.28
( neutral )

0.52
( weak )

-0.28
( neutral )

GeneOne Life Science, Finansinės ataskaitos

Annual	2023
Pajamos:	KRW40.20B
Bruto pelnas:	KRW-14.98B (-37.27 %)
EPS:	KRW-1 000.23

FY	2023
Pajamos:	KRW40.20B
Bruto pelnas:	KRW-14.98B (-37.27 %)
EPS:	KRW-1 000.23

FY	2022
Pajamos:	KRW48.72B
Bruto pelnas:	KRW9.34B (19.16 %)
EPS:	KRW-492.35

FY	2021
Pajamos:	KRW38.70B
Bruto pelnas:	KRW8.76B (22.63 %)
EPS:	KRW-218.13

Financial Reports:

No articles found.

GeneOne Life Science,

GeneOne Life Science, Inc., a biopharmaceutical company, engages in the development and contract manufacturing of gene-based-biomedicines. Its products comprise GLS-1027, which is in Phase I clinical trial for treatment of nephropathy and inflammatory diseases; GLS-1200 that is in Phase II clinical trial to treat Rhinosinusitis; GLS-1027 and GLS-1200, which is Phase II clinical trial for treatment of COVID-19. The company also develops GLS-3000 and GLS-5310 for the treatment of SARS-CoV-2; GLS-5100 to treat VZV-Shingles; and GLS-5140 for the treatment of SFTS. In addition, it is developing GLS-5300, which is in Phase II clinical trial for MERS; GLS-5700 that is in Phase I clinical trial for Zika; and GLS-6150, which is in Phase I clinical trial for treatment of hepatitis C, as well as GLS-6100 that is in pre-clinical stage for hepatitis C. Further, the company, through its subsidiary, VGXI, Inc., engages in the cGMP production of nucleic acid-based products, including DNA plasmids and mRNA. The company was formerly known as VGX International Inc. and changed its name to GeneOne Life Science, Inc. in April 2014. GeneOne Life Science, Inc. was founded in 1976 and is headquartered in Seoul, South Korea.